Exparel 266 MG/20 ML vial 20ML
Ended Awarded Last action
- Contract number
- SPE2DR26FHCY8
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $12,811
Award facts
- Contract value 100% obligated
- $12,811.30 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $12,811.30 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of EXPAREL 266 mg/20 ml vials. EXPAREL is a liposomal bupivacaine formulation used for surgical anesthesia and post-operative pain management. The firm fixed-price delivery order was awarded on December 12, 2025, with an ultimate completion date of January 6, 2026, and carries no set-aside designation, reflecting the vendor's competitive capability in unrestricted federal procurement. The order will be fulfilled at DMS Pharmaceutical Group's Park Ridge facility.
This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $499.999 billion master contract awarded November 13, 2025, with a completion date of December 31, 2036. The PPV-G GEN V program represents part of the broader $30.3 billion DLA pharmaceutical supply strategy designed to support recurring medical supply needs across Department of Defense healthcare facilities worldwide. DMS Pharmaceutical Group's established performance on numerous delivery orders demonstrates its capability to serve as a critical pharmaceutical supplier for military medical operations globally, supplying an extensive portfolio including branded and generic prescription medications, biologics, vaccines, and specialty surgical products to support defense healthcare operations.
Quick answers
Who was awarded contract SPE2DR26FHCY8?
SPE2DR26FHCY8 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 12, 2025.
How much is contract SPE2DR26FHCY8 worth?
The government has obligated $12,811 on SPE2DR26FHCY8.
Is contract SPE2DR26FHCY8 an order under another contract?
Yes. SPE2DR26FHCY8 is a delivery order under SPE2DR25D9207, an indefinite delivery contract.
Was contract SPE2DR26FHCY8 competed?
The extent of competition for SPE2DR26FHCY8 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award